Transdermal oestrogen therapy as a second-line hormonal intervention in prostate cancer: A bad experience

BJU International

Volumn 99, Issue 1, 2007, Pages 53-55

  Kandola, Sandhir ^a   Anyamene, Nicola ^a   Payne, Heather ^a   Harland, Stephen ^a,b,c  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Hormone therapy; Prostate cancer; Transdermal oestrogen

Indexed keywords

DIETHYLSTILBESTROL; ESTRADIOL; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; HORMONE SUBSTITUTION; HUMAN; INDIGESTION; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SKIN MANIFESTATION;

ADMINISTRATION, CUTANEOUS; ANTINEOPLASTIC AGENTS, HORMONAL; ESTRADIOL; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 33845484066     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06543.x     Document Type: Article

References (10)

1. UK HM Government: National Statistics. Cancer. http://www.statistics.gov. uk/CCI/nugget.asp?ID=920&Pos=6&ColRank=2&Rank=224. Accessed August 2006
2. UK HM Government: National Statistics. Prostate Cancer, key statistics. http://www.statistics.gov.uk/StatBase/xsdataset.asp?More=Y&vlnk= 3352&All=Y&B2.x=62&B2.y=22. Accessed August 2006
3. Hellerstedt B. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer. Urology 2003; 62 (Suppl. 1): 79-86
4. De Voogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S. Cardiovascular side effects of diethylstilboestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for treatment of advanced prostate cancer: results from European Organisation for Research on Treatment of Cancer trials 30761 and 30762. J Urol 1986; 135: 303-7
5. Scherr DS, Pitts WR Jr. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. J Urol 2003; 170: 1703-8
6. Gerber GS, Zagaja GP, Ray PS, Rukstalis DB. Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology 2000; 55: 97-101
7. Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD. Transdermal estradiol therapy for advanced prostate cancer - forward to the past? J Urol 2003; 169: 1735-7
8. Ockrim JL, Lalani EN, Kakkar AK, Abel PD. Transdermal oestradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism. J Urol 2005; 174: 527-33
9. Robertson CN, Roberson KM, Padilla GM et al. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst 1996; 88: 908-17
10. Bland LB, Garzotto M, DeLoughery TG et al. Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer 2005; 103: 717-23